Stephen L Garland

List of Publications by Year
in descending order

14	514	1040056 9	1125743 13
papers	citations	h-index	g-index

16	16	16	847
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot. Chemical Science, 2016, 7, 3869-3878.	7.4	8
2	What is the potential of G protein-coupled receptor allosteric sites in drug design?. Future Medicinal Chemistry, 2014, 6, 729-732.	2.3	2
3	Are GPCRs Still a Source of New Targets?. Journal of Biomolecular Screening, 2013, 18, 947-966.	2.6	133
4	Editorial [Hot Topic: Methods for the Successful Application of Chemogenomics to GPCR Drug Design (Guest Editors: Stephen L. Garland & David E. Gloriam)]. Current Topics in Medicinal Chemistry, 2011, 11, 1870-1871.	2.1	10
5	A Ligands View of Target Similarity: Chemogenomic Binding Site- Directed Techniques for Drug Discovery. Current Topics in Medicinal Chemistry, 2011, 11, 1872-1881.	2.1	15
6	The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 759-762.	2.2	23
7	Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1368-1372.	2.2	10
8	An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs. Drug Discovery Today: Technologies, 2010, 7, e87-e94.	4.0	13
9	Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochemical and Biophysical Research Communications, 2010, 391, 437-442.	2.1	39
10	The Discovery of a Selective, Small Molecule Agonist for the Mas-Related Gene X1 Receptor. Journal of Medicinal Chemistry, 2009, 52, 818-825.	6.4	15
11	Definition of the G Protein-Coupled Receptor Transmembrane Bundle Binding Pocket and Calculation of Receptor Similarities for Drug Design. Journal of Medicinal Chemistry, 2009, 52, 4429-4442.	6.4	100
12	(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3402-3406.	2.2	40
13	5-Aryl-pyrazolo[3,4-b]pyridines: Potent Inhibitors of Glycogen Synthase Kinase-3 (GSK-3).. ChemInform, 2003, 34, no.	0.0	0
14	5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1577-1580.	2.2	103